Trevena Inc Cash Flow Conversion Efficiency
Trevena Inc cash flow conversion efficiency. Based on the latest financial reports, Trevena Inc (TRVN) has a cash flow conversion efficiency ratio of 0.193x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.50 Million) by net assets ($-23.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Trevena Inc (2011–2023)
Cash flow conversion efficiency of Trevena Inc from 2011 to 2023. This chart illustrates how Trevena Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Trevena Inc stock price today for real-time trading data and today's change.
Trevena Inc Cash Flow Conversion Ratio Explained
Trevena Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Trevena Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevena Inc ranked by their cash flow conversion efficiency. Also see Trevena Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:IPTDA
|
N/A |
|
Auddia Inc
NASDAQ:AUUDW
|
-0.436x |
|
CareMax Inc
NASDAQ:CMAX
|
0.165x |
|
Ordinary Fully Paid Deferred Settlement
AU:RCMDB
|
N/A |
|
Ore Resources Limited
AU:OR3
|
N/A |
|
Yugo Metals Limited
AU:YUG
|
N/A |
|
Ethernity Networks Ltd
LSE:ENET
|
-1.768x |
|
Minerals Exploration Limited
AU:MEX
|
N/A |
Annual Cash Flow Conversion Efficiency for Trevena Inc (2011–2023)
The table below shows the annual cash flow conversion efficiency of Trevena Inc from 2011 to 2023. Review Trevena Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-7.66 Million | $-33.03 Million | 4.314x | +230.74% |
| 2022-12-31 | $15.60 Million | $-51.48 Million | -3.300x | -324.88% |
| 2021-12-31 | $64.63 Million | $-50.20 Million | -0.777x | -277.81% |
| 2020-12-31 | $104.07 Million | $-21.39 Million | -0.206x | +73.87% |
| 2019-12-31 | $30.08 Million | $-23.67 Million | -0.787x | -28.77% |
| 2018-12-31 | $41.53 Million | $-25.38 Million | -0.611x | +70.30% |
| 2017-12-31 | $34.63 Million | $-71.25 Million | -2.057x | -76.59% |
| 2016-12-31 | $78.58 Million | $-91.55 Million | -1.165x | -316.12% |
| 2015-12-31 | $143.13 Million | $-40.07 Million | -0.280x | +30.17% |
| 2014-12-31 | $99.20 Million | $-39.78 Million | -0.401x | +35.50% |
| 2013-12-31 | $38.99 Million | $-24.24 Million | -0.622x | -100.16% |
| 2012-12-31 | $-39.18K | $-14.81 Million | 377.866x | +43962.15% |
| 2011-12-31 | $15.42 Million | $-13.28 Million | -0.861x | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more